Overview: Phenobarbitone TestIntroduction: The Phenobarbitone Test measures phenobarbitone levels to monitor epilepsy treatment, preventing seizures. Following 2023 AAN guidelines, it uses biochemical methods for high specificity, supporting drug monitoring. This test is critical for guiding treatment adjustments, ensuring therapeutic levels, and improving outcomes in biochemistry for patients with epilepsy.
Other Names: Phenobarbitone Assay, Barbiturate Level Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Phenobarbitone monitoring began in the 1910s with its use in epilepsy. Biochemical methods improved in the 2000s, enhancing precision.
Purpose: Measures phenobarbitone levels to monitor epilepsy treatment, guides dosing, and prevents seizures.
Test Parameters: 1. Phenobarbitone Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of seizures or epilepsy treatment.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document seizures, epilepsy diagnosis, or phenobarbitone use. Include current medications, especially other anticonvulsants.
Consent: Written consent required, detailing the tests purpose, epilepsy treatment implications, and risks of sample collection.
Procedural Considerations: Uses liquid chromatography to measure phenobarbitone levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for epilepsy drug monitoring.
Factors Affecting Result Accuracy: Drug interactions or sample hemolysis can affect results. Improper timing of sample collection may reduce accuracy.
Clinical Significance: Therapeutic levels ensure seizure control, guiding dose adjustments. Subtherapeutic or toxic levels may require alternative therapies.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: EEG, serum electrolytes, or other anticonvulsant levels to monitor epilepsy treatment.
Test Limitations: Drug interactions may affect levels; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Epilepsy Guidelines, 2023; Neurology, Kwan P, 2022.
